Walach H, Sherr J, Schneider R, Shabi R, Bond A, Rieberer G
Department of Evaluation Research in Complementary Medicine, Samueli Institute--European Office, Institute for Environmental Medicine and Hospital Epidemiology, University Hospital Freiburg, Germany.
Homeopathy. 2004 Oct;93(4):179-85. doi: 10.1016/j.homp.2004.07.006.
Homeopathic pathogenetic trials (HPTs) (provings) are the pillar of homeopathy. Symptoms experienced by healthy volunteers are used to find the correct medicine for therapy. It is unclear whether these symptoms are specific or due to placebo noise. Furthermore, it is uncertain whether proving effects, if present at all, are due to a local or non-local process
To develop a test model which allows for testing if homeopathic proving symptoms are caused by placebo or causative mechanisms, and if these symptoms are due to local or non-local processes.
Randomised, blinded, placebo-controlled, parallel-group study, with 1-week baseline and 2-weeks proving period.
11 healthy volunteers from two different homeopathic schools. PROVING SUBSTANCE: An homeopathic medicine (Cantharis 30c), blindly chosen from 12 potential medicines, compared to placebo.
Number of symptoms typical for the medicine in the experimental and control group during baseline and proving period.
During baseline there was no difference in the number of typical or atypical symptoms in either group. During the proving period, both more typical symptoms for Cantharis (P= 0.03) and more atypical symptoms (P= 0.02) were observed compared to baseline. Between-group differences were not significant. Effect sizes for the difference between the proving and control group for typical symptoms was d=0.4, and for atypical symptoms d=0.6.
This proving model could be valuable in studying the validity of proving symptoms of homeopathic substances in healthy volunteers.
Homeopathic proving symptoms appear to be specific to the medicine and do not seem to be due to a local process. Since this was a pilot study using a small number of provers, rival hypotheses cannot be ruled out and the study needs replication.
顺势疗法致病性试验(HPTs)(验证试验)是顺势疗法的支柱。健康志愿者所经历的症状用于寻找正确的治疗药物。尚不清楚这些症状是特异性的还是由安慰剂效应引起的。此外,也不确定验证效应(如果确实存在)是由于局部还是非局部过程所致。
建立一个测试模型,以检验顺势疗法验证症状是由安慰剂还是致病机制引起的,以及这些症状是由于局部还是非局部过程所致。
随机、双盲、安慰剂对照、平行组研究,有1周的基线期和2周的验证期。
来自两所不同顺势疗法学校的11名健康志愿者。验证物质:从12种潜在药物中随机选择的一种顺势疗法药物(斑蝥30c),与安慰剂进行比较。
基线期和验证期实验组和对照组中该药物典型症状的数量。
在基线期,两组中典型或非典型症状的数量没有差异。在验证期,与基线期相比,观察到斑蝥的典型症状更多(P = 0.03),非典型症状也更多(P = 0.02)。组间差异不显著。验证组与对照组典型症状差异的效应量为d = 0.4,非典型症状的效应量为d = 0.6。
该验证模型对于研究健康志愿者中顺势疗法药物验证症状的有效性可能具有重要价值。
顺势疗法验证症状似乎对药物具有特异性,似乎不是由局部过程引起的。由于这是一项使用少量验证者的试点研究,不能排除其他竞争性假设,该研究需要重复进行。